What Is IQLT? iShares MSCI Intl Quality Factor ETF

MSCI's quality definition rests on three measures: high return on equity, low year-to-year variability in earnings growth, and low debt to equity. None of them concerns price. That is the crucial distinction from a value fund, which starts with what a company costs. Quality starts with how the business performs and is largely indifferent to the multiple, which is why quality portfolios can look expensive on conventional metrics while still meeting their own criteria.

Applied outside the United States, those three tests produce a recognisable list: Nestle, Roche, Novartis, AstraZeneca, Allianz and Zurich Insurance. Consumer staples and pharmaceuticals score well on earnings stability, and large European insurers score well on returns and balance sheet strength. This is the part of the portfolio most people expect when they buy an international quality fund.

The top ten holdings come to 24.3% of assets, which is fairly concentrated for an international fund covering multiple regions. Weighting by quality score alongside size means the highest scorers get meaningfully more capital than a plain cap-weighted fund would give them, and ASML at 6.6% is the clearest example.

ASML is 6.6% of the fund, close to triple the next largest position. Add Tokyo Electron and Advantest at 1.7% each and the semiconductor equipment cluster reaches 10.0%. This is not a thematic choice by a manager. It is what happens when you rank developed non-US companies by return on equity and balance sheet strength: the firms that supply the tools every chipmaker needs have unusually high returns on capital, because their markets are close to duopolies.

The consequence is a cyclical exposure hiding inside a defensive-sounding label. Semiconductor equipment orders follow capital spending decisions at a handful of chip manufacturers, and those decisions swing hard. A fund with a tenth of its assets in that supply chain will move with the capital expenditure cycle regardless of how stable the earnings of its pharmaceutical holdings are.

It is also worth noting how the source data displays these companies. ASML appears under its Amsterdam listing, Roche and Novartis under Swiss listings, AstraZeneca under its London listing, and Advantest and Tokyo Electron under Tokyo listings. These are ordinary local lines for well-known multinationals, not obscure securities.

The reported sector weights are financials 25%, industrials 17%, technology 13%, healthcare 9% and consumer discretionary 8%. Financials leading is a feature of European and Japanese markets generally, and the quality screen keeps the better-capitalised insurers and banks rather than the whole sector. ABB at 2.2% carries much of the industrials weight.

Everything here is priced in euros, Swiss francs, yen, sterling and other currencies, and the fund does not hedge that back to the dollar. For a US-based holder, currency movement is a separate return stream that can dominate the stock-level result over shorter periods. That is not a defect, but it means the fund's behaviour differs from a US quality fund even when the underlying businesses are similar.

At 0.30% the fee sits below what most active international managers charge and above the cheapest cap-weighted international index funds. That gap is the price of the factor screen. IQLT suits an investor who wants developed international exposure filtered for balance sheet strength and profitability. It is a weaker fit for someone seeking full international market coverage, since it excludes emerging markets entirely and holds only the companies that pass the quality test.

Approximate weights as of August 2026. Each ticker links to its individual stock guide in Walnut.

There are three common ways to get IQLT exposure. Buy shares (or fractional shares) of IQLT directly at any major broker that lists it. Hold it as a core position and layer more concentrated ideas on top. Or build it into a thematic portfolio in Walnut, so IQLT sits alongside other holdings that express the same thesis, with target weights you can rebalance toward. IQLT trades like a stock during market hours, so you buy it the same way you would any listed share.

New to buying funds? See how to buy an ETF, step by step.

Whether IQLT is a good buy depends less on any single call and more on your time horizon and what you already hold: it tracks an MSCI index of developed-market companies outside the United States screened for return on equity, stable earnings growth and low financial leverage, so the real question is whether you want that exposure in your mix and at what weight. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is IQLT a buy?

IQLT gives you an MSCI index of developed-market companies outside the United States screened for return on equity, stable earnings growth and low financial leverage exposure in one ticker at a 0.30% expense ratio. Most investors use it as a core holding and layer more concentrated thematic portfolios on top.

Whether IQLT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is IQLT a buy?

IQLT yields 2.41% as of August 2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see IQLT dividend: yield and schedule.

New to funds like IQLT? Start with what an ETF is, then how to buy an ETF, or browse the full guide to ETF investing.